Skip to main content
letter
. 2022 Feb 23;24(6):1029–1031. doi: 10.1093/neuonc/noac026

Fig. 1.

Fig. 1

Clinical course for the two cases [Patient 1-panel (A), Patient 2-panel (B)], with corresponding MRI, histopathology, immunohistochemistry (IHC), and molecular data. IHC panel included CD34, chromogranin A, EMA, GFAP, Ki-67, myelin basic protein, NeuN CC2, neurofilament, p53, S100, INI1, H3K27me3. Cells of both tumors were immunopositive for S100, GFAP, INI1, p53, H3K27me3.